載入中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新資料
US$1.08
US$0.00 · 0.00%
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
前收盤價
US$1.08
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
日內區間
目前US$1.08
52週區間
目前US$1.08
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
2
估值過高
情緒
51
多空交錯
風險
47
風險偏高
動能
76
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Talphera, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapeutic products intended for use in carefully monitored medical environments. Their lead experimental candidate is Niyad, a lyophilized (freeze-dried) formulation of nafamostat. This anticoagulant is currently being assessed under an investigational device exemption for its application in extracorporeal circuits. The company's development pipeline also features LTX-608, a potential anti-inflammatory and antiviral agent being explored for the treatment of numerous conditions, including COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, Talphera is advancing Fedsyra, a pre-filled syringe containing ephedrine, and PFS-02, a pre-filled syringe containing phenylephrine. Established in 2005, the company was previously known as AcelRx Pharmaceuticals, Inc. It adopted the name Talphera, Inc. in January 2024 and maintains its corporate headquarters in San Mateo, California.
日內區間
目前US$1.08
52週區間
目前US$1.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2.8萬 USD | — | 65.1萬 USD | — | 37.8萬 USD |
| 銷貨成本 | — | 671.8萬 USD | 554.6萬 USD | 164.7萬 USD | 300.6萬 USD |
| 毛利 | 2.8萬 USD | −671.8萬 USD | −489.5萬 USD | −164.7萬 USD | −262.8萬 USD |
| 研究與開發 | 603.3萬 USD | 671.8萬 USD | 554.6萬 USD | 169.4萬 USD | 243.5萬 USD |
| 銷售、一般及管理費用 | 747.9萬 USD | — | — | 1701.1萬 USD | — |
| 營業費用 | 1351.2萬 USD | 853.4萬 USD | 1199.4萬 USD | 1870.5萬 USD | 1548.8萬 USD |
| 利息收入 | 43.6萬 USD | 67.9萬 USD | 673.6萬 USD | 150.2萬 USD | 316.2萬 USD |
| 利息支出 | — | 39.4萬 USD | 13.4萬 USD | 111.6萬 USD | 229.1萬 USD |
| 折舊和攤銷 | — | 9.6萬 USD | 31.1萬 USD | 164.7萬 USD | 197.3萬 USD |
| 營業利益 | −1348.4萬 USD | −1525.2萬 USD | −1688.9萬 USD | −2035.2萬 USD | −1811.6萬 USD |
| 淨利 | −1429萬 USD | −1300.4萬 USD | −1839.7萬 USD | 4251.5萬 USD | −3509.9萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
